BRPI0507856A - composição farmacêutica, e, processo para preparar o anticorpo abeta - Google Patents
composição farmacêutica, e, processo para preparar o anticorpo abetaInfo
- Publication number
- BRPI0507856A BRPI0507856A BRPI0507856-3A BRPI0507856A BRPI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- pharmaceutical composition
- abeta antibody
- abeta
- free
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507856A true BRPI0507856A (pt) | 2007-07-10 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507856-3A BRPI0507856A (pt) | 2004-02-23 | 2005-02-17 | composição farmacêutica, e, processo para preparar o anticorpo abeta |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (enExample) |
| EP (1) | EP1720909B1 (enExample) |
| JP (1) | JP4851348B2 (enExample) |
| KR (2) | KR20090005410A (enExample) |
| CN (1) | CN1922209B (enExample) |
| AT (1) | ATE534667T1 (enExample) |
| AU (1) | AU2005217596B2 (enExample) |
| BR (1) | BRPI0507856A (enExample) |
| CA (1) | CA2556436C (enExample) |
| CY (1) | CY1112162T1 (enExample) |
| DK (1) | DK1720909T3 (enExample) |
| EA (1) | EA009872B1 (enExample) |
| ES (1) | ES2375627T3 (enExample) |
| IL (1) | IL177611A (enExample) |
| NO (1) | NO20064239L (enExample) |
| PL (1) | PL1720909T3 (enExample) |
| PT (1) | PT1720909E (enExample) |
| SI (1) | SI1720909T1 (enExample) |
| UA (1) | UA93181C2 (enExample) |
| WO (1) | WO2005082939A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| PT2099826E (pt) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| AU2008204335B2 (en) | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2650308A3 (en) * | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| MX2011005481A (es) | 2008-11-25 | 2011-08-17 | Biogen Idec Inc | Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso. |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| AR078986A1 (es) | 2009-11-12 | 2011-12-14 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| AU2011282536B2 (en) | 2010-07-30 | 2015-12-24 | Ac Immune S.A. | Safe and functional humanized anti beta-amyloid antibody |
| DK3339323T3 (da) * | 2010-08-12 | 2020-01-20 | Lilly Co Eli | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| CN103796679B (zh) | 2011-06-23 | 2016-10-19 | 比奥根国际神经科学公司 | 抗-α突触核蛋白结合分子 |
| EP3970725B1 (en) | 2012-09-07 | 2025-08-20 | Massachusetts Eye & Ear Infirmary | A gamma secretase inhibitor for treating hearing loss |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| EP3683232A1 (en) | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2017200762A2 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
| WO2018031334A1 (en) * | 2016-08-11 | 2018-02-15 | Eli Lilly And Company | Aminothiazines and their use as bace1 inhibitors |
| AU2018321335B2 (en) | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP2025506411A (ja) | 2022-02-03 | 2025-03-11 | イーライ リリー アンド カンパニー | アルツハイマー病の診断及び治療のための局所タウイメージング |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901343T2 (xx) | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| IL151378A0 (en) * | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2318006T3 (es) * | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
-
2005
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112162T1 (el) | 2015-12-09 |
| US20070190046A1 (en) | 2007-08-16 |
| EP1720909A2 (en) | 2006-11-15 |
| CA2556436A1 (en) | 2005-09-09 |
| JP2008500279A (ja) | 2008-01-10 |
| SI1720909T1 (sl) | 2012-01-31 |
| IL177611A (en) | 2013-05-30 |
| WO2005082939A2 (en) | 2005-09-09 |
| CN1922209B (zh) | 2012-09-05 |
| ES2375627T3 (es) | 2012-03-02 |
| DK1720909T3 (da) | 2012-01-30 |
| UA93181C2 (ru) | 2011-01-25 |
| IL177611A0 (en) | 2006-12-10 |
| KR100889430B1 (ko) | 2009-03-23 |
| JP4851348B2 (ja) | 2012-01-11 |
| NO20064239L (no) | 2006-11-20 |
| AU2005217596A1 (en) | 2005-09-09 |
| ATE534667T1 (de) | 2011-12-15 |
| CN1922209A (zh) | 2007-02-28 |
| EA200601545A1 (ru) | 2007-02-27 |
| EA009872B1 (ru) | 2008-04-28 |
| CA2556436C (en) | 2014-04-01 |
| WO2005082939A3 (en) | 2005-10-27 |
| KR20090005410A (ko) | 2009-01-13 |
| AU2005217596B2 (en) | 2012-01-19 |
| PT1720909E (pt) | 2011-12-23 |
| PL1720909T3 (pl) | 2012-04-30 |
| EP1720909B1 (en) | 2011-11-23 |
| KR20060126785A (ko) | 2006-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1720909T3 (da) | Anti-Abeta antistof | |
| NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
| TW200745161A (en) | Stable antibody formulation | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| CY2018013I2 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
| CL2011000010A1 (es) | Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende. | |
| DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
| CL2010000426A1 (es) | Anticuerpo humano que se une al ligando para el ox40 (ox40l o gp34) humano; metodo de produccion; y composicion farmaceutica que lo comprende (div. sol. n°2389-05). | |
| CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
| CY1111896T1 (el) | Απαραβιαστες φαρμακευτικες μορφες δοσολογιας δια του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο | |
| CO5720212A1 (es) | Composicion de anticuerpo her2 | |
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| NO345046B1 (no) | Oral doseringsform | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| CY1110026T1 (el) | Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων | |
| CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| CL2008000935A1 (es) | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. | |
| UA104297C2 (en) | Anti-il-12/il-23 antibody | |
| BRPI0508064A (pt) | flavivìrus, composição de vacina e molécula de ácido nucléico | |
| EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| EA200800601A1 (ru) | Связывающие fas антитела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |